Drug Type Blood components |
Synonyms Bovine haemoglobin HbO2 Therapeutics, Bovine hemoglobin, Hemoglobin glutamer250 (bovine) HbO2 Therapeutics + [4] |
Target |
Mechanism Hemoglobins modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date ZA (12 Dec 2005), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Transfusion Reaction | ZA | 30 Jan 2006 | |
Anemia | ZA | 12 Dec 2005 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wounds and Injuries | NDA/BLA | GB | 30 Sep 2009 | |
Myocardial Ischemia | Phase 2 | - | 30 Sep 2009 | |
Acute Coronary Syndrome | Phase 2 | NL | 01 Apr 2007 | |
Coronary Occlusion | Phase 2 | NL | 01 Apr 2007 | |
Coronary Artery Disease | Phase 2 | GR | 01 Feb 2006 | |
Coronary Artery Disease | Phase 2 | ZA | 01 Feb 2006 | |
Coronary Artery Disease | Phase 2 | GB | 01 Feb 2006 | |
Shock | Phase 2 | ZA | - | |
Neoplasms | Phase 1 | US | 06 Sep 2000 | |
Myocardial Infarction | Discovery | US | 30 Sep 2009 |
Not Applicable | - | kdtsbtzgqg(ifvvxkllmb) = tzyifcjmrn grwwlqyqdb (hglbnvqvmx ) | - | 20 Apr 2018 | |||
Voluven | kdtsbtzgqg(ifvvxkllmb) = uizqxuuiep grwwlqyqdb (hglbnvqvmx ) |